The Scottish Hepatology Access Research Partnership (SHARP) improving access to liver services throughout Scotland.

Autor:	Lynch R; Department of Hepatology, NHS Tayside, Dundee, Scotland, UK., Fallowfield J; Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, Scotland, UK., Blane D; University of Glasgow, Glasgow, Scotland, UK., Swann R; NHS Greater Glasgow and Clyde, Glasgow, Scotland, UK., Mills K; Patient representative, Inverness, UK., Cordwell A; British Liver Trust, Ringwood, England, UK., Forrest E; NHS Greater Glasgow and Clyde, Glasgow, Scotland, UK.
Jazyk:	angličtina
Zdroj:	NIHR open research [NIHR Open Res] 2024 Nov 27; Vol. 4, pp. 58. Date of Electronic Publication: 2024 Nov 27 (Print Publication: 2024).
DOI:	10.3310/nihropenres.13650.2
Abstrakt:	Background and Aims: Scotland has the highest rate of deaths from chronic liver disease (CLD) in the UK. Socioeconomic and geographic isolation represent significant challenges to delivery of care. The multidisciplinary Scottish Hepatology Access Research Partnership (SHARP) aimed to identify and break down barriers to diagnosing and treating liver disease in Scotland. Methods: SHARP comprised a core Partnership Management Group that developed projects and a Partnership Advisory Group which provided oversight. Results: SHARP established workstreams to achieve its aims: Understanding current access to liver services To identify barriers to liver patient care in Scotland we audited liver services and surveyed the experience of patients (n=276); primary care physicians (n=199) and Gastroenterologists/Hepatologists (n=99). Technologies to monitor and diagnose CLD Liver disease is diagnosed and monitored using routine blood testing which disadvantages isolated patients. We plan to develop a point of use test to analyse ALT and AST to enable community-based identification and monitoring of liver disease. Identification of patients at risk of liver disease CLD is often diagnosed late. We propose developing an artificial intelligence tool to predict an individual's risk of an emergent admission to hospital due to CLD. This tool will be validated in a Welsh cohort. Barriers to engagement with care for liver disease Hepatology did-not-attend rates are the highest of any specialty. We propose research to co-design a suite of recommendations to improve engagement with care for CLD patients. We aim to achieve this by interviewing practitioners alongside patients who do and don't engage with services. Conclusions: Through a national survey SHARP has developed an understanding of the issues affecting access to hepatology services in Scotland. SHARP has developed projects that will help address the issues that socioeconomically and geographically isolated patients face when it comes to identifying and treating liver disease. Competing Interests: No competing interests were disclosed. (Copyright: © 2024 Lynch R et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu